Tenaya Therapeutics Ownership
| TNYA Stock | USD 2.04 0.11 5.12% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Tenaya |
Tenaya Stock Ownership Analysis
About 73.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.27. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tenaya Therapeutics recorded a loss per share of 1.53. The entity had not issued any dividends in recent years. Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company was incorporated in 2016 and is headquartered in South San Francisco, California. Tenaya Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 135 people. To find out more about Tenaya Therapeutics contact Faraz MBA at 650 825 6990 or learn more at https://www.tenayatherapeutics.com.Besides selling stocks to institutional investors, Tenaya Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Tenaya Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Tenaya Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Tenaya Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Tenaya Therapeutics Insider Trades History
Only 1.18% of Tenaya Therapeutics are currently held by insiders. Unlike Tenaya Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Tenaya Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Tenaya Therapeutics' insider trades
Tenaya Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Tenaya Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tenaya Therapeutics backward and forwards among themselves. Tenaya Therapeutics' institutional investor refers to the entity that pools money to purchase Tenaya Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Fmr Inc | 2024-06-30 | 1.3 M | Geode Capital Management, Llc | 2024-06-30 | 1.2 M | State Street Corp | 2024-06-30 | 1 M | Euclidean Capital Llc | 2024-06-30 | 1 M | Adage Capital Partners Gp Llc | 2024-06-30 | 1000 K | Alphabet Inc | 2024-06-30 | 915.7 K | Stepstone Group Llc | 2024-06-30 | 462.2 K | Northern Trust Corp | 2024-06-30 | 394 K | Schonfeld Strategic Advisors Llc | 2024-06-30 | 357.5 K | Column Group Llc | 2024-06-30 | 9.4 M | Ra Capital Management, Llc | 2024-06-30 | 7.6 M |
Tenaya Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tenaya Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tenaya Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tenaya Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tenaya Therapeutics Outstanding Bonds
Tenaya Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tenaya Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tenaya bonds can be classified according to their maturity, which is the date when Tenaya Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Tenaya Therapeutics Corporate Filings
| 17th of September 2024 Other Reports | ViewVerify | |
8K | 16th of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 19th of August 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
F4 | 16th of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| F | Ford Motor | |
| CRM | Salesforce |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tenaya Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Tenaya Stock refer to our How to Trade Tenaya Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tenaya Therapeutics. If investors know Tenaya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tenaya Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.53) | Return On Assets (0.41) | Return On Equity (0.75) |
The market value of Tenaya Therapeutics is measured differently than its book value, which is the value of Tenaya that is recorded on the company's balance sheet. Investors also form their own opinion of Tenaya Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Tenaya Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tenaya Therapeutics' market value can be influenced by many factors that don't directly affect Tenaya Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tenaya Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tenaya Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tenaya Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.